A director at Conmed Corp bought 3,000 shares at 68.300USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
The independent financial analyst theScreener just downgraded the general evaluation of CONMED (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title loses a star(s) and now shows 1 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as moderately risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Neutral. As of the analysis date Nove...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Key Points: • A few Consumer Discretionary names continue to act well. The list is thinning of attractive names though. (ex. FOXF, UEIC, DECK, CHDN, WING, YUM, BOOT, RCI, POOL, DLTR, and AAN) • A number of Health Care Sector names are attractive. (ex. MASI, TFX, CNMD, STE, CRVL, LNTH, HAE, COO, WST, RGEN, ANIK, NEO, and TECH) • Attractive Technology and Services names include: MANH, CDNS, ANSS, AGYS, TTEC, CLGX, MMS, and KBR
No-moat Conmed reported first-quarter results that largely met our expectations, and we don’t foresee many changes to our model that will push our $60 fair value estimate significantly in either direction. Segment revenue and non-GAAP profits were consistent with our view, although GAAP profitability and cash flow suffered from higher interest expense and additional costs associated with the ongoing integration of Buffalo Filter. Organic revenue growth clocked in at 6.3%, toward the high end o...
No-moat Conmed reported first-quarter results that largely met our expectations, and we don’t foresee many changes to our model that will push our $60 fair value estimate significantly in either direction. Segment revenue and non-GAAP profits were consistent with our view, although GAAP profitability and cash flow suffered from higher interest expense and additional costs associated with the ongoing integration of Buffalo Filter. Organic revenue growth clocked in at 6.3%, toward the high end o...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Key Points: • Health Care Equipment & Supplies remains a leadership area in the Health Care Sector. • A number of Biotechnology stocks are making major reversals with many hitting 52-week RS highs. • Semiconductors, Semi-Suppliers, and Electronic Components remain as leadership Groups.
Conmed has undergone significant change since 2014, after shaking up most of the board and C-suite executives in response to an activist shareholder’s campaign against the firm. Curt Hartman, former CFO and interim-CEO of Stryker, was installed as CEO to lead a turnaround at the company, replacing the founding Corosanti family leadership. After business segment restructuring efforts, a re-alignment of salesforce incentives, and a handful of acquisitions, Hartman's strategy appears to be on the...
Conmed reported fourth-quarter and full-year 2018 results that exceeded our revenue expectations, while falling roughly in line with our outlook for operating profitability. As we roll and update our model, we'll likely raise our fair value estimate by roughly 10% to account for the cash flows received since our last update, along with slightly higher margin assumptions helped by the inclusion of the pending Buffalo Filter transaction. The firm's strong performance has been fairly broad-based th...
Conmed reported fourth-quarter and full-year 2018 results that exceeded our revenue expectations, while falling roughly in line with our outlook for operating profitability. As we roll and update our model, we'll likely raise our fair value estimate by roughly 10% to account for the cash flows received since our last update, along with slightly higher margin assumptions helped by the inclusion of the pending Buffalo Filter transaction. The firm's strong performance has been fairly broad-based t...
Summary Marketline's VentriPoint Diagnostics Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by VentriPoint Diagnostics Ltd. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive break...
Conmed reported fourth-quarter and full-year 2018 results that exceeded our revenue expectations, while falling roughly in line with our outlook for operating profitability. As we roll and update our model, we'll likely raise our fair value estimate by roughly 10% to account for the cash flows received since our last update, along with slightly higher margin assumptions helped by the inclusion of the pending Buffalo Filter transaction. The firm's strong performance has been fairly broad-based t...
Conmed reported fourth-quarter and full-year 2018 results that exceeded our revenue expectations, while falling roughly in line with our outlook for operating profitability. As we roll and update our model, we'll likely raise our fair value estimate by roughly 10% to account for the cash flows received since our last update, along with slightly higher margin assumptions helped by the inclusion of the pending Buffalo Filter transaction. The firm's strong performance has been fairly broad-based th...
Summary Marketline's Teleflex Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Teleflex Incorporated since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the o...
After market close on Dec. 13, no-moat Conmed announced its intent to purchase privately held Buffalo Filter for $365 million. Preliminary adjustments to our model suggest the transaction is roughly neutral to our existing $55 per share fair value estimate. We've been expecting management to pursue another deal as the firm reduced its leverage profile following the 2016 acquisition of SurgiQuest. However, while we think the strategic rationale for the deal is sound, the price management is payi...
No-moat Conmed reported third-quarter results that largely tracked our expectations, after handily beating our forecasts for the first half of 2018. We don’t anticipate making many changes to our model, and don't foresee a material change to our $55 per share fair value estimate. Our valuation implies approximately 22.5 times and 12.5 times our 2019 forecasts for adjusted earnings and EBITDA, respectively. Overall, the firm grew revenue 8.1% in constant currency with general surgery continuin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.